The antifungal mechanism of EntV-derived peptides is associated with a reduction in extracellular vesicle release
PLOS Pathogens · 2025
DOI: 10.1371/journal.ppat.1013519 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2025. Verfasst von Giuseppe Buda De Cesare und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Molecular Genetics, University of Texas McGovern Medical School, Houston, Texas, United States of America. Hauptthemen laut MEDLINE: Extracellular Vesicles, Candida albicans, Antifungal Agents, Candidiasis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIDCR NIH HHS, NIH.
Abstract (Originalsprache)
Candida albicans , an opportunistic fungal pathogen, causes systemic and superficial infections, especially in immunocompromised patients. Treatment of fungal infections is complicated by limited antifungal options and the development of drug resistance. Previous work from our group demonstrated the efficacy of the anti-virulence peptide EntV and shorter variants against C. albicans infection in various animal models, including mouse models of oropharyngeal candidiasis and disseminated infection and a rat venous catheter model. However, the mechanism of action, which abrogates fungal virulence without fungicidal or fungistatic activity, has remained unknown. We used a combination of cell biological, biochemical, genomic, and genetic approaches to identify this mechanism. We demonstrate that EntV-based peptides bind to the fungal cell envelope in a punctate and dynamic manner, co-localizing with extracellular vesicles (EVs), which play a critical role in fungal biofilm formation and virulence. Transcriptomic and genetic analyses further indicate that this activity is linked to the intracellular vesicular trafficking machinery, especially the ESCRT pathway, as mutations in this pathway alter sensitivity to EntV peptides and regulate virulence. We also show that EntV treatment significantly reduces EV secretion in C. albicans , supporting a novel mechanism of antifungal action through inhibition of EV-mediated virulence. These findings further develop EntV as a promising anti-virulence agent with potential for therapeutic development against drug-resistant fungal pathogens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Molecular Genetics, University of Texas McGovern Medical School, Houston, Texas, United States of America.
- Department of Medical Microbiology and Immunology, University of Wisconsin, Madison, Wisconsin, United States of America.
- Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
- Department of Genetics, The Blavatnik Institute, Harvard Medical School, Boston, Massachusetts, United States of America.
ORCID-Profile: Michael C Lorenz
Förderung
- NIAID NIH HHS
- NIDCR NIH HHS
- NIH
Zitieren
APA
Buda De Cesare, G., Cruz, M. R., Cristy, S. A., Vega, L. A., Zarnowski, R., Zito, A., Guha, S., Andes, D. R., Garsin, D. A., & Lorenz, M. C. (2025). The antifungal mechanism of EntV-derived peptides is associated with a reduction in extracellular vesicle release. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1013519
Vancouver
Buda De Cesare G, Cruz MR, Cristy SA, Vega LA, Zarnowski R, Zito A, et al. The antifungal mechanism of EntV-derived peptides is associated with a reduction in extracellular vesicle release. PLOS Pathogens. 2025. doi:10.1371/journal.ppat.1013519
BibTeX
@article{BudaDeCesare2025,
author = {Buda De Cesare, Giuseppe and Cruz, Melissa R and Cristy, Shane A and Vega, Luis A and Zarnowski, Robert and Zito, Antonino and Guha, Shantanu and Andes, David R and Garsin, Danielle A and Lorenz, Michael C},
title = {The antifungal mechanism of EntV-derived peptides is associated with a reduction in extracellular vesicle release},
journal = {PLOS Pathogens},
year = {2025},
doi = {10.1371/journal.ppat.1013519}
}
EUVIMED